Nivo-lution in mesothelioma

Aaron S. Mansfield; Marjorie G. Zauderer

doi:10.1158/1078-0432.CCR-19-1836

Nivo-lution in mesothelioma

Aaron S. Mansfield
, Marjorie G. Zauderer

Medical Oncology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.

Original language	English (US)
Pages (from-to)	5438-5440
Number of pages	3
Journal	Clinical Cancer Research
Volume	25
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-19-1836
State	Published - Sep 15 2019

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-19-1836

Cite this

@article{61cd0eb3013c406d9fa79e35ba016358,

title = "Nivo-lution in mesothelioma",

abstract = "The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.",

author = "Mansfield, \{Aaron S.\} and Zauderer, \{Marjorie G.\}",

note = "Publisher Copyright: {\textcopyright} 2019 American Association for Cancer Research.",

year = "2019",

month = sep,

day = "15",

doi = "10.1158/1078-0432.CCR-19-1836",

language = "English (US)",

volume = "25",

pages = "5438--5440",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - Nivo-lution in mesothelioma

AU - Mansfield, Aaron S.

AU - Zauderer, Marjorie G.

PY - 2019/9/15

Y1 - 2019/9/15

N2 - The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.

AB - The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.

UR - https://www.scopus.com/pages/publications/85072234485

UR - https://www.scopus.com/pages/publications/85072234485#tab=citedBy

U2 - 10.1158/1078-0432.CCR-19-1836

DO - 10.1158/1078-0432.CCR-19-1836

M3 - Article

C2 - 31315884

AN - SCOPUS:85072234485

SN - 1078-0432

VL - 25

SP - 5438

EP - 5440

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

Nivo-lution in mesothelioma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this